Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects
Article first published online: 23 JUL 2014
© 2014 Royal College of Obstetricians and Gynaecologists
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 122, Issue 6, pages 785–794, May 2015
How to Cite
Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG 2015;122:785–794..
- Issue published online: 18 APR 2015
- Article first published online: 23 JUL 2014
- Manuscript Accepted: 3 JUN 2014
- ISS-Ministry of Health (Italy) on AIDS and Opportunistic Infections
- Candida albicans ;
- vulvovaginal candidiasis
Although a number of fungal species belonging to the genus Candida can cause acute vulvovaginal infection (VVC), Candida albicans is by far the most prevalent etiological agent, particularly for the most severe chronic condition known as recurrent vulvovaginal candidiasis (RVVC). This review focuses on recent advances in pathogenic mechanisms and host immune responses to C. albicans and on the utilisation of this information in the development of a vaccine to prevent and/or treat vaginal candidiasis. Currently, two vaccines with main or sole RVVC as clinical indication have completed a phase 1 clinical trial, and one of them has entered a phase 2 trial.